We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Gsk Plc | LSE:GSK | London | Ordinary Share | GB00BN7SWP63 | ORD 31 1/4P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
5.00 | 0.29% | 1,733.50 | 1,732.50 | 1,733.00 | 1,739.50 | 1,724.50 | 1,733.00 | 4,237,056 | 16:35:18 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 30.33B | 4.93B | 1.1970 | 14.48 | 71.35B |
Date | Subject | Author | Discuss |
---|---|---|---|
29/7/2020 13:15 | Companies would die for GSK two billion cash flow each quarter. | montyhedge | |
29/7/2020 13:14 | I thought they said full year eps guidance still intact.See what directors say at 2pm.19p dividend in the bag. | montyhedge | |
29/7/2020 13:11 | Miserable market reaction to not too bad results! Especially since the price has tumbled over the last week in anticipation of worse figures. | tradermichael | |
29/7/2020 12:59 | Poor results. Another dividend magnet with zero growth and now the likelihood of dividend cut. Years of getting behind the curve re drug development now catching up with them. Will buy in when they get back to 13 quid. | porsche1945 | |
29/7/2020 12:30 | Results presentation A webcast of the quarterly results presentation hosted by Emma Walmsley, GSK CEO, will be held at 2pm BST on 29 July 2020. Presentation materials will be published on www.gsk.com prior to the webcast and a transcript of the webcast will be published subsequently. | tradermichael | |
29/7/2020 12:30 | Solid 5% dividend payer, cheque on the doormat every 13 weeks. | montyhedge | |
29/7/2020 12:29 | MONSTER RALLLYYYYYYY imminent on this one below guys DNL = 3x Approvals expected during next 2 months including an Orphan Drug with FDA decision on September 29 = CHEAPEST UK Biotech a potential 500%++ GEM Diurnal Group (DNL) = MCap £42 M / Cash £15 M or enough untill early 2022 / LOTS of BIG milestones on the way = Still the MOST attractive and CHEAPEST pharma stock in UK has potential to run toward 200p very fast especially on approval of Alkindi in USA (expected in September) and Chronocort in Europe (expected in Q1 ) =STRONG BUY AGGRESSIVE a sleeping giant here .GL Market Cap £42 million Cash £15 million Price 35p Alkindi approval in Australia expected this Quarter Alkindi approval in Israel expected this Quarter FDA decision for Alkindi on September 29 EMA Decision for Chronocort expected in early Q1 2021 | ih_752952 | |
29/7/2020 12:25 | I worked for Yellow Pages Sales Ltd in Surbiton way back in the day and on missing a monthly sales target, attempted to 'explain' this to my the manager - he said to me 'reasons, excuses, bullsh1t' - I never missed another target!. GSK - lots of reasons, lots of excuses (some valid in this case), I wont use the other word. | essentialinvestor | |
29/7/2020 12:17 | Be adding more if drops to 1570 | andyadvfn1 | |
29/7/2020 12:13 | Lol let's hope so, very much doubt it, investors looking for safe dividend paying companies. Not many about. | montyhedge | |
29/7/2020 12:12 | Waiting for the right moment to buy, 5% yield I can live that in these markets. | montyhedge | |
29/7/2020 12:11 | TEST OF £15 coming up | onehanded | |
29/7/2020 12:09 | Nope, not gonna like them one little bit. Hence buying opportunity? | thamestrader | |
29/7/2020 12:08 | Market does not like the results then | watfordhornet | |
29/7/2020 12:07 | Another 19p dividend in the bag, figures has forecast by CEO. | montyhedge | |
29/7/2020 09:26 | Sanofi/GSK not being bias I think will be the winning vaccine. Sanofi great track record with influenza vaccines. | montyhedge | |
29/7/2020 08:52 | "expects a Phase 1/2 study to start in September" Still at incredibly early stages. If successful, well into 2021 and seems behind the crowd. | alphorn | |
29/7/2020 08:51 | Sanofi, GSK Agree With UK Government to Supply Up to 60 Million Doses of Covid-19 VaccineSource: Dow Jones News By Ian Walker Sanofi S.A. and GlaxoSmithKline PLC said Wednesday that they have reached an agreement with the U.K. government to supply up to 60 million doses of a Covid-19 vaccine, subject to final contract.The French and U.K. pharmaceutical companies said the vaccine candidate is based on Sanofi's technology that produces an influenza vaccine as well as GSK's pandemic adjuvant technology.Sanofi is leading clinical development and registration of the Covid-19 vaccine and plans a Phase 1, 2 study in September, followed by a Phase 3 study by the end of the year. If data proves positive, regulatory approval could be received in the first half of next year, it said.spud | spud | |
29/7/2020 08:48 | Of course they will set in stone, these quarterly dividends. | montyhedge | |
29/7/2020 08:39 | How do you know that? They have not declared a dividend payment for 13 August - have to wait till after 12.00 noon today? | tradermichael | |
29/7/2020 08:31 | Another 19p in the bag. Pharma's, software tech, gold, the only place to be in these markets. | montyhedge | |
29/7/2020 08:03 | Yes I know. | montyhedge | |
29/7/2020 07:48 | Monty: x div date will be 13 August .... ;0) | tradermichael | |
29/7/2020 07:25 | Good news on the vaccine, promising potential. | our haven | |
28/7/2020 18:50 | Markets expecting a 1% to 4% drop in revenue that's priced in at current shareprice. | montyhedge |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions